Metered Dose Inhalers Market Research Report Information By Product (Press Metered Dose Inhalers, Breath Actuated Metered Dose Inhalers), By Propellant Type (HFA 134A, HFA 227EA, HFA 152A), By Technology (Pulmonary Platform Technologies, Nasal Platform Technologies), By Indication (Asthma, COPD, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Metered Dose Inhalers Market Overview

The Metered Dose Inhalers Market was valued at USD 15.8 billion in 2023. The industry is projected to grow from USD 17.1 billion in 2024 to USD 30.0 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.43% during the forecast period (2024 - 2032). The rising prevalence of respiratory diseases, increasing product launches by market players and growing awareness and education are fueling the growth of the global metered-dose inhaler market.Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Metered Dose Inhalers Market Trends

Increasing product launch by market players

The increasing availability of new metered dose inhaler (MDI) products is a key driver of growth in the global MDI market. These launches bring about technological advancements such as improved drug delivery systems and ergonomic designs, which cater to patient preferences for ease of use and adherence. Novel formulations and combinations offer more therapeutic options for a variety of respiratory conditions, improving treatment efficacy and patient outcomes. Competitive dynamics among pharmaceutical companies drive innovation and affordability, providing healthcare providers and patients with a wider range of high-quality MDI options. Furthermore, strategic market expansion into new geographies and targeted solutions for specific patient populations drive market growth, making MDI products indispensable in the management of respiratory diseases around the world.

For instance, in February 2022, Aptar Pharma (US) launched HeroTracker Sense, a cutting-edge digital health solution that aims to convert standard metered dose inhalers (pMDIs) into smart, connected healthcare devices. This innovation aims to improve the management and adherence of patients with chronic respiratory diseases such as asthma, COPD, cystic fibrosis, and respiratory conditions exacerbated by COVID-19. HeroTracker Sense attaches to an MDI canister and includes advanced sensors to monitor critical aspects of inhalation technique and medication adherence. In 2020, Zydus Cadila (India) launched Forglyn pMDI, India's first pressurized metered dose inhaler (pMDI) for patients with chronic obstructive pulmonary disease. These innovations, exemplified by products like Aptar Pharma’s HeroTracker Sense and Zydus Cadila’s Forglyn pMDI, cater to diverse respiratory conditions, improving treatment efficacy and patient outcomes worldwide. Competitive dynamics foster innovation and affordability, expanding market reach and reinforcing MDIs as essential tools in managing respiratory diseases globally.

Metered Dose Inhalers Market Segment Insights

Global Metered Dose Inhalers Product Insight

Based on product, the Metered Dose Inhalers Market has been segmented into Press Metered Dose Inhalers and Breath actuated Metered Dose Inhalers. The Press Metered Dose Inhalers segment held the largest market share in 2023, and the Breath actuated Metered Dose Inhalers segment is the fastest-growing segment during the forecast period, 2024–2032.

The Press Metered Dose Inhalers are experiencing robust growth due to several key drivers. The increased incidence of respiratory conditions including asthma and Chronic Obstructive Pulmonary Disease (COPD), which is driving up demand for effective and convenient medication delivery methods. Furthermore, the aging population is a major factor driving the metered dose inhaler (MDI) market's expansion because they are more prone to long-term respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD).

FIGURE 2: METERED DOSE INHALERS MARKET SIZE, BY PRODUCT, 2023 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Global Metered Dose Inhalers Propellant Type Insight

Based on propellant type, the Metered Dose Inhalers Market has been segmented into HFA 134a, HFA 227ea, and HFA-152a. The HFA 134a segment held the largest market in 2023 and the HFA-152a segment is the fastest growing segment during the forecast period, 2024–2032.

A greater focus is also being placed on lessening the environmental effect of inhalers, which has prompted the creation and use of environmentally friendly propellants such hydrofluoroalkanes (HFAs). For instance, in March 2022, Koura (US) opened the world’s first HFA 152a medicinal propellant production facility allowing pharmaceutical companies to fulfil the 2025–2026 commercial product deadlines. Pressurized Metered Dosage Inhalers (pMDIs) will use low global warming potential (GWP) propellants, which will be produced in the new HFA 152a production facility. With the new propellant, pMDI inhalers' carbon footprint can be lowered by up to 90%, to the same degree as a dry powder inhaler (DPI). Furthermore, in May 2024, Kindeva Drug Delivery (UK) announced that, it is making significant strides in advancing sustainable inhaler technology with its recent announcement of a second manufacturing line at its Loughborough, U.K., facility. This new line, set to be operational by 2026, will produce pressurized metered-dose inhalers (pMDIs) using low-global warming potential (GWP) propellants, specifically HFA-152a and HFO-1234ze, which have GWP reductions of 90% and 99.9% compared to the current standard, HFA-134a. The investment aims to meet the rising demand for eco-friendly inhaler options in response to stringent European Union F-gas regulations and growing industry emphasis on sustainability.

Global Metered Dose Inhalers Technology Insight

Based on technology, the Metered Dose Inhalers Market has been segmented into pulmonary platform technologies and nasal platform technologies. The pulmonary platform technologies segment held the largest market in 2023, and the nasal platform technologies segment is the fastest growing segment during the forecast period, 2024-2032.

Global Metered Dose Inhalers Indication Insight

Based on indication, the Metered Dose Inhalers Market has been segmented into Asthma, COPD, and others. The asthma segment held the largest market in 2023 and is the fastest growing segment during the forecast period, 2024-2032.

The increased incidence of respiratory conditions including asthma and Chronic Obstructive Pulmonary Disease (COPD), which is driving up demand for effective and convenient medication delivery methods. For instance, as per the American Medical Association, Worldwide, the estimated prevalence of COPD in 2020 was 10.6% for both males and females, or 480 million cases. It was predicted that by 2050, there will be 592 million cases of COPD worldwide (9.5% of the eligible population), representing a relative rise of 23.3% from 2020 to 2050 of 112 million cases. Moreover, in 2019, the Global Burden of Disease (GBD) study estimated that asthma was responsible for 21.6 million disability-adjusted life years (DALYs) worldwide across all age groups. Asthma was ranked as the 34th leading cause of global disease burden, accounting for 20% of total DALYs from chronic respiratory diseases. A significant portion of this burden, nearly half, was attributed to years lived with disability (YLD), which totaled 10.2 million. Furthermore, asthma was ranked 24th among the leading causes of YLD globally, with males having a slightly higher burden than females.

Global Metered Dose Inhalers Distribution Channel Insight

Based on distribution channel, the Metered Dose Inhalers Market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest market in 2023, and the online pharmacies segment is the fastest growing segment during the forecast period.

The rising number of hospital admissions for respiratory conditions requiring inhaler treatments and increasing focus on comprehensive patient care and management within hospital settings are driving the hospital pharmacies segment.

Global Metered Dose Inhalers Regional Insights

Based on region, the Global Metered Dose Inhaler Market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest market share in 2023. However, Asia-Pacific is projected to grow at the highest CAGR during the forecast period, 2024-2032

The Metered Dose Inhalers market in North America is characterized by robust growth driven by technological advancements, a supportive regulatory environment, and increasing healthcare needs. Moreover, sophisticated healthcare infrastructure and substantial investment in research and development, enabling the creation of cutting-edge Metered Dose Inhalers drives the market. Furthermore, rising awareness and education campaigns about respiratory health and inhaler usage and development of eco-friendly and sustainable propellants for metered dose inhalers present avenues for growth. Moreover, strategic partnership and collaborations are fuelling the demand for metered dose inhalers in North America. For instance, in February 2022, Honeywell collaborated with AstraZeneca to create and market next-generation respiratory inhalers that treat asthma and chronic obstructive pulmonary disease (COPD) using propellants with near-zero global warming potential (GWP).

The Americas region is followed by Europe, which is further segmented into the Germany, France, UK, Italy, Spain, and Rest of the Europe. The Metered Dose Inhalers market in Europe is marked by increasing healthcare expenditure and well-established healthcare infrastructure. The comprehensive insurance coverage and reimbursement policies for respiratory treatments and established market presence of leading pharmaceutical companies and research institutions—are propelling the demand for Metered Dose Inhalers market. The increasing prevalence of respiratory diseases, driven by an aging population, further amplifies the need for sophisticated, high-quality metered dose inhalers. For instance, according to European Commission, On January 1, 2023, the EU population was anticipated to be 448.8 million individuals, with more than one-fifth (21.3%) of those aged 65 years or older.

Asia-Pacific is expected to witness significant growth and is projected to be the fastest growing region over the forecast period and experiencing robust growth driven by several key factors. Rapid growing healthcare infrastructure and increasing investments in healthcare infrastructure across countries like China, India, and Japan are fueling demand for sophisticated inhalers. The rising prevalence of respiratory diseases, and an aging population further drive the need for innovative solutions.  For instance, as per the Asia-Pacific Report on Population Ageing 2022, there were approximately 670 million people aged 60 or older in Asia-Pacific in 2022. Also, it has been estimated that the number will double to approximately 1.3 billion people by 2050 in Asia-Pacific. Additionally, the region’s growing focus on enhancing healthcare access and affordability creates significant opportunities for Metered Dose Inhalers. Favorable regulatory environments in emerging markets and supportive government initiatives also contribute to market expansion. Furthermore, strategic partnerships and collaborations with local medical device manufacturers enhance the ability of Metered Dose Inhalers to scale operations and meet the diverse needs of the regional market.

FIGURE 3: METERED DOSE INHALERS MARKET BY REGION 2023 & 2032 (USD BILLION)

Global Metered Dose Inhalers Key Market Players & Competitive Insights

The global metered dose inhaler market is distinguished by the presence of numerous regional and local players catering to the global metered dose inhaler market. Furthermore, the increasing prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis, continuous innovations in inhalation device technology, including improvements in aerosol delivery systems, propellants, and dose counters, increase the efficacy, safety, and convenience of use of MDIs, and many patients prefer inhalation therapy to oral drugs because of its focused distribution to the lungs, quick beginning of action, and fewer systemic side effects. This preference motivates the acceptance of MDIs as a preferred alternative for addressing respiratory diseases and is further driving the growth of the global metered dose inhaler market during the forecast period.

The global metered dose inhaler market is extremely competitive, with players competing and investing heavily in development of innovative products to gain a significant market share. The market is moderately fragmented with high competition in the market, increasing partnerships, and introducing new products and increasing portfolio attractiveness.

The growth of prominent industry players is dependent on various factors, such as market conditions, product differentiation and innovation, and pricing strategies. It is also projected that a rise in the investments for new product launches and the shift towards online purchasing will also boost the market's growth in the upcoming future.

Lupin Pharmaceuticals is one of the largest generic pharmaceutical companies in the world, with a significant presence in over 100 countries and offering a diverse portfolio of over 1000 products. It is known for its expertise in developing, manufacturing, and marketing a wide range of generic and branded pharmaceuticals, as well as active pharmaceutical ingredients (APIs) across various therapeutic segments. They are expanding their portfolio with complex generics platforms focused on inhalation, injectables, and biosimilars.

In July 2023, Hormosan Pharma GmbH, Lupin's German subsidiary, has launched Luforbec100/6 (beclometasone 100µg / for moterol 6µg), a pressurized metered dose inhaler (pMDI) for treating adult asthma and chronic obstructive pulmonary disease (COPD) in Germany.

Key Companies in the Metered Dose Inhalers Market include

• AstraZeneca (UK)


• GSK PLC. (UK)


• Organon (US)


• Cipla, Inc. (India)


• Lupin Pharmaceuticals, Inc. (India)


• Zydus Group (India)


• Teva Pharmaceutical Industries Ltd. (Israel)


• Viatris Inc. (US)


• Aristopharma Ltd. (Bangladesh)


• Beximco Pharmaceuticals Limited (Bangladesh)

Global Metered Dose Inhalers Industry Developments

July 2023: Hormosan Pharma GmbH, Lupin's German subsidiary, has launched Luforbec100/6 (beclometasone 100µg / for moterol 6µg), a pressurized metered dose inhaler (pMDI) for treating adult asthma and chronic obstructive pulmonary disease (COPD) in Germany.

January 2023: AstraZeneca announced that Airsupra received FDA approval for the prevention or treatment of bronchoconstriction as needed, as well as to lower the risk of exacerbations in individuals with asthma who are 18 years of age or older.

February 2022: Honeywell collaborated with AstraZeneca to create and market next-generation respiratory inhalers that treat asthma and chronic obstructive pulmonary disease (COPD) using propellants with near-zero global warming potential (GWP).

October 2020: Zydus Cadila has announced the launch of Forglyn pMDI, India's first pressurized Metered Dose Inhaler (pMDI) with a combination of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting Beta Agonist (LABA) for patients with Chronic Obstructive Pulmonary Disease (COPD.

August 2020: Lupin Limited announced that the US Food and Drug Administration (FDA) has approved its Albuterol Sulfate Inhalation Aerosol, 90 mcg (base)/actuation, a generic version of ProAir HFA. Lupin's generic Albuterol Sulphate MDI will be produced at its Indore (Unit III) facility in India.

Metered Dose Inhalers Market Segmentation

• Global Metered Dose Inhalers Product Outlook
  
  
  
  • Press Metered Dose Inhalers
  
  
  • Breath Actuated Metered Dose Inhalers
  
  
  
  

• Global Metered Dose Inhalers Propellant Type Outlook
  
  
  
  • HFA 134A
  
  
  • HFA 227EA
  
  
  • HFA-152A
  
  
  
  


• Global Metered Dose Inhalers Technology Outlook
  
  
  
  • Pulmonary Platform Technologies
  
  
  • Nasal Platform Technologies
  
  
  
  


• Global Metered Dose Inhalers Indication Outlook
  
  
  
  • Asthma
  
  
  • COPD
  
  
  • Others
  
  
  
  


• Global Metered Dose Inhalers Distribution Channel Outlook
  
  
  
  • Hospital Pharmacies
  
  
  • Retail Pharmacies
  
  
  • Online Pharmacies
  
  
  
  


• Global Metered Dose Inhalers Regional Outlook


• North America
  
  
  
  • US
  
  
  • Canada
  
  
  • Mexico
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East & Africa
  
  
  • South America